Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off‐label in the first wave of COVID‐19
We applied a set of in silico and in vitro assays, compliant with the CiPA (Comprehensive In Vitro Proarrhythmia Assay) paradigm, to assess the risk of chloroquine or hydroxychloroquine‐mediated QT prolongation and Torsades de Pointes (TdP), alone and combined with erythromycin and azithromycin, dru...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Wiley
2021
|
| _version_ | 1797060862012293120 |
|---|---|
| author | Delaunois, A Abernathy, M Anderson, WD Beattie, KA Chaudhary, KW Coulot, J Gryshkova, V Hebeisen, S Holbrook, M Kramer, J Kuryshev, Y Leishman, D Lushbough, I Passini, E Redfern, WS Rodriguez, B Rossman, EI Trovato, C Wu, C Valentin, J |
| author_facet | Delaunois, A Abernathy, M Anderson, WD Beattie, KA Chaudhary, KW Coulot, J Gryshkova, V Hebeisen, S Holbrook, M Kramer, J Kuryshev, Y Leishman, D Lushbough, I Passini, E Redfern, WS Rodriguez, B Rossman, EI Trovato, C Wu, C Valentin, J |
| author_sort | Delaunois, A |
| collection | OXFORD |
| description | We applied a set of in silico and in vitro assays, compliant with the CiPA (Comprehensive In Vitro Proarrhythmia Assay) paradigm, to assess the risk of chloroquine or hydroxychloroquine‐mediated QT prolongation and Torsades de Pointes (TdP), alone and combined with erythromycin and azithromycin, drugs repurposed during the first wave of COVID‐19. Each drug or drug combination was tested in patch clamp assays on 7 cardiac ion channels, in in silico models of human ventricular electrophysiology (Virtual Assay®) using control (healthy) or high‐risk cell populations, and in human induced pluripotent stem cell (hiPSC)‐derived cardiomyocytes. In each assay, concentration‐response curves encompassing and exceeding therapeutic free plasma levels were generated. Both chloroquine and hydroxychloroquine showed blocking activity against some potassium, sodium and calcium currents. Chloroquine and hydroxychloroquine inhibited IKr (IC50: 1µM and 3‐7µM, respectively) and IK1 currents (IC50: 5 and 44µM, respectively). When combining hydroxychloroquine with azithromycin, no synergistic effects were observed. The two macrolides had no or very weak effects on the ion currents (IC50>300‐1000µM). Using Virtual Assay®, both antimalarials affected several TdP indicators, chloroquine being more potent than hydroxychloroquine. Effects were more pronounced in the high‐risk cell population. In hiPSC‐derived cardiomyocytes, all drugs showed early‐after‐depolarizations, except azithromycin. Combining chloroquine or hydroxychloroquine with a macrolide did not aggravate their effects. In conclusion, our integrated nonclinical CiPA dataset confirmed that, at therapeutic plasma concentrations relevant for malaria or off‐label use in COVID‐19, chloroquine and hydroxychloroquine use is associated with a proarrhythmia risk, which is higher in populations carrying predisposing factors but not worsened with macrolide combination. |
| first_indexed | 2024-03-06T20:22:55Z |
| format | Journal article |
| id | oxford-uuid:2e7118ef-55ad-45d6-91dd-2f90766551c7 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T20:22:55Z |
| publishDate | 2021 |
| publisher | Wiley |
| record_format | dspace |
| spelling | oxford-uuid:2e7118ef-55ad-45d6-91dd-2f90766551c72022-03-26T12:49:02ZApplying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off‐label in the first wave of COVID‐19Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:2e7118ef-55ad-45d6-91dd-2f90766551c7EnglishSymplectic ElementsWiley2021Delaunois, AAbernathy, MAnderson, WDBeattie, KAChaudhary, KWCoulot, JGryshkova, VHebeisen, SHolbrook, MKramer, JKuryshev, YLeishman, DLushbough, IPassini, ERedfern, WSRodriguez, BRossman, EITrovato, CWu, CValentin, JWe applied a set of in silico and in vitro assays, compliant with the CiPA (Comprehensive In Vitro Proarrhythmia Assay) paradigm, to assess the risk of chloroquine or hydroxychloroquine‐mediated QT prolongation and Torsades de Pointes (TdP), alone and combined with erythromycin and azithromycin, drugs repurposed during the first wave of COVID‐19. Each drug or drug combination was tested in patch clamp assays on 7 cardiac ion channels, in in silico models of human ventricular electrophysiology (Virtual Assay®) using control (healthy) or high‐risk cell populations, and in human induced pluripotent stem cell (hiPSC)‐derived cardiomyocytes. In each assay, concentration‐response curves encompassing and exceeding therapeutic free plasma levels were generated. Both chloroquine and hydroxychloroquine showed blocking activity against some potassium, sodium and calcium currents. Chloroquine and hydroxychloroquine inhibited IKr (IC50: 1µM and 3‐7µM, respectively) and IK1 currents (IC50: 5 and 44µM, respectively). When combining hydroxychloroquine with azithromycin, no synergistic effects were observed. The two macrolides had no or very weak effects on the ion currents (IC50>300‐1000µM). Using Virtual Assay®, both antimalarials affected several TdP indicators, chloroquine being more potent than hydroxychloroquine. Effects were more pronounced in the high‐risk cell population. In hiPSC‐derived cardiomyocytes, all drugs showed early‐after‐depolarizations, except azithromycin. Combining chloroquine or hydroxychloroquine with a macrolide did not aggravate their effects. In conclusion, our integrated nonclinical CiPA dataset confirmed that, at therapeutic plasma concentrations relevant for malaria or off‐label use in COVID‐19, chloroquine and hydroxychloroquine use is associated with a proarrhythmia risk, which is higher in populations carrying predisposing factors but not worsened with macrolide combination. |
| spellingShingle | Delaunois, A Abernathy, M Anderson, WD Beattie, KA Chaudhary, KW Coulot, J Gryshkova, V Hebeisen, S Holbrook, M Kramer, J Kuryshev, Y Leishman, D Lushbough, I Passini, E Redfern, WS Rodriguez, B Rossman, EI Trovato, C Wu, C Valentin, J Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off‐label in the first wave of COVID‐19 |
| title | Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off‐label in the first wave of COVID‐19 |
| title_full | Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off‐label in the first wave of COVID‐19 |
| title_fullStr | Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off‐label in the first wave of COVID‐19 |
| title_full_unstemmed | Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off‐label in the first wave of COVID‐19 |
| title_short | Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off‐label in the first wave of COVID‐19 |
| title_sort | applying the cipa approach to evaluate cardiac proarrhythmia risk of some antimalarials used off label in the first wave of covid 19 |
| work_keys_str_mv | AT delaunoisa applyingthecipaapproachtoevaluatecardiacproarrhythmiariskofsomeantimalarialsusedofflabelinthefirstwaveofcovid19 AT abernathym applyingthecipaapproachtoevaluatecardiacproarrhythmiariskofsomeantimalarialsusedofflabelinthefirstwaveofcovid19 AT andersonwd applyingthecipaapproachtoevaluatecardiacproarrhythmiariskofsomeantimalarialsusedofflabelinthefirstwaveofcovid19 AT beattieka applyingthecipaapproachtoevaluatecardiacproarrhythmiariskofsomeantimalarialsusedofflabelinthefirstwaveofcovid19 AT chaudharykw applyingthecipaapproachtoevaluatecardiacproarrhythmiariskofsomeantimalarialsusedofflabelinthefirstwaveofcovid19 AT coulotj applyingthecipaapproachtoevaluatecardiacproarrhythmiariskofsomeantimalarialsusedofflabelinthefirstwaveofcovid19 AT gryshkovav applyingthecipaapproachtoevaluatecardiacproarrhythmiariskofsomeantimalarialsusedofflabelinthefirstwaveofcovid19 AT hebeisens applyingthecipaapproachtoevaluatecardiacproarrhythmiariskofsomeantimalarialsusedofflabelinthefirstwaveofcovid19 AT holbrookm applyingthecipaapproachtoevaluatecardiacproarrhythmiariskofsomeantimalarialsusedofflabelinthefirstwaveofcovid19 AT kramerj applyingthecipaapproachtoevaluatecardiacproarrhythmiariskofsomeantimalarialsusedofflabelinthefirstwaveofcovid19 AT kuryshevy applyingthecipaapproachtoevaluatecardiacproarrhythmiariskofsomeantimalarialsusedofflabelinthefirstwaveofcovid19 AT leishmand applyingthecipaapproachtoevaluatecardiacproarrhythmiariskofsomeantimalarialsusedofflabelinthefirstwaveofcovid19 AT lushboughi applyingthecipaapproachtoevaluatecardiacproarrhythmiariskofsomeantimalarialsusedofflabelinthefirstwaveofcovid19 AT passinie applyingthecipaapproachtoevaluatecardiacproarrhythmiariskofsomeantimalarialsusedofflabelinthefirstwaveofcovid19 AT redfernws applyingthecipaapproachtoevaluatecardiacproarrhythmiariskofsomeantimalarialsusedofflabelinthefirstwaveofcovid19 AT rodriguezb applyingthecipaapproachtoevaluatecardiacproarrhythmiariskofsomeantimalarialsusedofflabelinthefirstwaveofcovid19 AT rossmanei applyingthecipaapproachtoevaluatecardiacproarrhythmiariskofsomeantimalarialsusedofflabelinthefirstwaveofcovid19 AT trovatoc applyingthecipaapproachtoevaluatecardiacproarrhythmiariskofsomeantimalarialsusedofflabelinthefirstwaveofcovid19 AT wuc applyingthecipaapproachtoevaluatecardiacproarrhythmiariskofsomeantimalarialsusedofflabelinthefirstwaveofcovid19 AT valentinj applyingthecipaapproachtoevaluatecardiacproarrhythmiariskofsomeantimalarialsusedofflabelinthefirstwaveofcovid19 |